German firm tests 'double chin' drug

January 10, 2011

German drugs giant Bayer said Monday it had launched tests into an injectable drug to combat the fat deposits that lead to the dreaded "double chin."

Bayer said in a statement it was conducting clinical trials into ATX-101, an injectable "for the reduction of localised under the chin (submental fat)."

The firm is testing some 720 people in 64 centres in Britain, France, Germany, Belgium, Spain and Italy with a view to launching a product in Europe, Asia and South America in 2014.

Jean-Paul Ortonne, a French involved in the trials, said: "There is a huge demand for a safe, effective and approved injectable treatment for localised fat reduction."

The tests are a step towards "a well-studied, clinically-proven treatment to reduce localised submental fat without surgery," he added.

Yvonne Moeller, a Bayer spokeswoman, described the procedure as "something like a tattoo."

Between 40 and 70 tiny injections are administered into the over several sessions, with the amount depending on the size of the double chin and the person, she told AFP.

"You would hope to see noticeable results after about 16 weeks," she added.

Related Stories

Recommended for you

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

geokstr
1 / 5 (1) Jan 10, 2011
Doctors in Beverly Hills will form a partnership to buy out the patent for this drug. After all, they've already invented a highly lucrative fix for this self-image-threatening condition.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.